MedTrace Logo

Relative Bioavailability Study of Emodepside IR-tablets and Solution

NCT03383523 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2020-03-09

Study results available
· View outcomes & findings →

Summary

This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they will be compared to the oral liquid service formulation (LSF) used in the FIH Single Ascending Dose study (DNDi-EMO-001 study) (CT.gov identifier: NCT02661178)

Conditions

  • Filariasis

Interventions

DRUG

Emodepside (BAY 44-4400)

2 tablets compared to the liquid formulation

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Drugs for Neglected Diseases

    lead OTHER

Principal Investigators

  • Jeremy Dennison · Hammersmith Medicines Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-26
Primary Completion
2018-03-26
Completion
2018-03-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03383523 on ClinicalTrials.gov